4-氯-3-吡唑甲醛 | 623570-54-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-氯-3-吡唑甲醛
• 中文别名: 4-氯-3-甲酰基吡唑
• 英文名称: 4-chloro-3-formylpyrazole
• 英文别名: 4-Chloro-1h-pyrazole-3-carbaldehyde；4-chloro-1H-pyrazole-5-carbaldehyde
• CAS: 623570-54-7
• 化学式: C₄H₃ClN₂O
• mdl: MFCD00110641
• 分子量: 130.534
• InChiKey: JCXMSYLXHJLALJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-((1r,4r)-4-((5-nitro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)cyclohexyl)acetonitrile 、 4-氯-3-吡唑甲醛 在 sodium dithionite 作用下， 以 甲醇 、 水 、 二甲基亚砜 为溶剂， 反应 7.0h， 以62.5%的产率得到2-((1r,4r)-4-(2-(4-chloro-1H-pyrazol-3-yl)-6-(phenylsulfonyl)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile
  参考文献：
  名称：

  [EN] IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES
  [FR] IMIDAZOPYRROLOPYRIDINE EN TANT QU'INHIBITEURS DE LA FAMILLE JAK DE KINASES

  摘要：

  2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile化合物，含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗由JAK介导的疾病状态、紊乱和疾病，如炎症性肠病的方法。

  公开号：

  WO2018112382A1

文献信息

• AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE
  申请人：Amgen Inc.

  公开号：US20140107109A1

  公开（公告）日：2014-04-17

  The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A 4 , A 5 , A 6 , A 8 , R 1 , R 2 , R 3 , R 7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-II.

  本发明提供了一类新的化合物，用于调节β-分泌酶（BACE）活性。这些化合物具有一般的化学式I： 其中化学式I中的变量A4、A5、A6、A8、R1、R2、R3、R7和n在此独立地被定义。该发明还提供了包含这些化合物的药物组合物，以及这些化合物和组合物用于治疗与A-beta斑块形成和沉积相关的疾病和/或症状的对应用途，这些疾病和症状是由BACE的生物活性引起的。这种由BACE介导的疾病包括阿尔茨海默病、认知缺陷、认知障碍、精神分裂症和其他中枢神经系统疾病。该发明还提供了化学式II的化合物及其亚式化合物，中间体和用于制备化学式I-II化合物的有用过程和方法。
• Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones:  A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases
  作者：Li Sun、Ngoc Tran、Flora Tang、Harald App、Peter Hirth、Gerald McMahon、Cho Tang

  DOI：10.1021/jm980123i

  日期：1998.7.1

  analysis for these compounds and their relative potency and selectivity to inhibit particular RTKs has determined that (1) 3-[(five-membered heteroaryl ring)methylidenyl]indolin-2-ones are highly specific against the VEGF (Flk-1) RTK activity, (2) 3-(substituted benzylidenyl)indolin-2-ones containing bulky group(s) in the phenyl ring at the C-3 position of indolin-2-ones showed high selectivity toward

  已经设计并合成了3-取代的吲哚-2-酮，作为一类新型的酪氨酸激酶抑制剂，该抑制剂对不同的受体酪氨酸激酶（RTK）具有选择性。已经评估了这些化合物对完整细胞中一组RTK的相对抑制特性。通过修饰3-取代的吲哚-2-酮，我们鉴定了在亚微摩尔水平下显示选择性抑制各种RTK的配体依赖性自磷酸化的化合物。这些化合物的结构活性分析及其抑制特定RTK的相对效能和选择性已确定（1）3-[（（五元杂芳基环）亚甲基]茚满-2-酮对VEGF（Flk-1 ）RTK活动，（2）在吲哚-2-酮的C-3位的C-3位置的苯环中含有庞大基团的3-（取代的苄基）吲哚啉-2-酮显示出对EGF和Her-2 RTK的高选择性，并且（ 3）在针对PDGF和VEGF（Flk-1）RTK进行测试时，在吲哚-2-酮（16）的C-3位置包含延伸的侧链的化合物表现出较高的效价和选择性。这些3-取代的吲哚-2-酮中的两个的最近公布的晶体学数据提供
• [EN] HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME<br/>[FR] COMPOSÉS HÉTÉROARYLIQUES POUVANT ÊTRE UTILISÉS EN TANT QU'INHIBITEURS DE L'ENZYME SAE
  申请人：MILLENNIUM PHARM INC

  公开号：WO2015002994A3

  公开（公告）日：2015-05-28
• Structure activity relationships of human galactokinase inhibitors
  作者：Li Liu、Manshu Tang、Martin J. Walsh、Kyle R. Brimacombe、Rajan Pragani、Cordelle Tanega、Jason M. Rohde、Heather L. Baker、Elizabeth Fernandez、Burchelle Blackman、James M. Bougie、William H. Leister、Douglas S. Auld、Min Shen、Kent Lai、Matthew B. Boxer

  DOI：10.1016/j.bmcl.2014.11.061

  日期：2015.2

  Classic Galactosemia is a rare inborn error of metabolism that is caused by deficiency of galactose-1-phosphate uridyltransferase (GALT), an enzyme within the Leloir pathway that is responsible for the conversion of galactose-1-phosphate (gal-1-p) and UDP-glucose to glucose-1-phosphate and UDPgalactose. This deficiency results in elevated intracellular concentrations of its substrate, gal-1-p, and this increased concentration is believed to be the major pathogenic mechanism in Classic Galactosemia. Galactokinase (GALK) is an upstream enzyme of GALT in the Leloir pathway and is responsible for conversion of galactose and ATP to gal-1-p and ADP. Therefore, it was hypothesized that the identification of a small-molecule inhibitor of human GALK would act to prevent the accumulation of gal-1-p and offer a novel entry therapy for this disorder. Herein we describe a quantitative high-throughput screening campaign that identified a single chemotype that was optimized and validated as a GALK inhibitor. Published by Elsevier Ltd.
• Bis diselenide-based schiff bases as deubiquitination signaling pathway modulators
  申请人：KING FAISAL UNIVERSITY

  公开号：US12006293B1

  公开（公告）日：2024-06-11

  Diselenide organo compounds, their synthesis, and their use as deubiquitination signaling pathway modulators and anti-cancer agents.